Fate Therapeutics Correlations
| FATE Stock | USD 1.13 0.02 1.74% |
The current 90-days correlation between Fate Therapeutics and Caribou Biosciences is 0.49 (i.e., Very weak diversification). The correlation of Fate Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Fate Therapeutics Correlation With Market
Modest diversification
The correlation between Fate Therapeutics and DJI is 0.25 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Related Correlations Analysis
| 0.92 | 0.82 | 0.43 | 0.85 | 0.97 | CRBU | ||
| 0.92 | 0.88 | 0.61 | 0.95 | 0.94 | CRSP | ||
| 0.82 | 0.88 | 0.4 | 0.84 | 0.81 | VERV | ||
| 0.43 | 0.61 | 0.4 | 0.7 | 0.51 | BEAM | ||
| 0.85 | 0.95 | 0.84 | 0.7 | 0.9 | PRME | ||
| 0.97 | 0.94 | 0.81 | 0.51 | 0.9 | SANA | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Fate Stock performing well and Fate Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Fate Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CRBU | 5.41 | 1.36 | 0.24 | 0.77 | 4.79 | 12.02 | 23.18 | |||
| CRSP | 2.85 | 0.66 | 0.22 | 0.56 | 2.83 | 7.09 | 16.14 | |||
| VERV | 5.61 | 2.50 | 0.50 | (1.79) | 3.28 | 9.83 | 83.78 | |||
| BEAM | 2.87 | 0.18 | 0.05 | 0.24 | 4.23 | 6.28 | 26.62 | |||
| PRME | 6.84 | 1.82 | 0.30 | 1.04 | 5.67 | 21.58 | 41.91 | |||
| SANA | 4.85 | 1.42 | 0.36 | 1.02 | 3.47 | 12.50 | 31.62 |
Fate Therapeutics Corporate Management
| Barbara Hickingbottom | Senior Development | Profile | |
| Tunde Babalola | Senior Operations | Profile | |
| Andrew Henry | Senior Operations | Profile | |
| Jessica Francis | Vice Operations | Profile | |
| YuWaye MD | Chief Officer | Profile | |
| Cindy Tahl | General Secretary | Profile | |
| Edward III | Chief Officer | Profile |